Key statistics
| Open | 0.00 |
|---|---|
| High | 6.12 |
| Low | 6.12 |
| Bid | -- |
| Offer | -- |
| Previous close | 6.12 |
| Average volume | -- |
|---|---|
| Shares outstanding | 9.29m |
| Free float | 9.29m |
| P/E (TTM) | -- |
| Market cap | 6.05m USD |
| EPS (TTM) | -1.02 USD |
Data delayed at least 15 minutes, as of Sep 16 2024 07:21 BST.
More ▼
Announcements
- Purple Biotech Achieves Toxicology Milestone Demonstrating an Expanded Therapeutic Window for CAPTN-3 Platform Tri-specific Antibody, IM1240
- Purple Biotech Reports Positive New Preclinical Data Demonstrating Multi-Arm Anti-Tumor Activity Across Two CAPTN-3 Tri-Specific Antibodies at ESMO Immuno-Oncology Congress 2025
- Purple Biotech to Present New Preclinical Data from its CAPTN-3 Tri-Specific Antibody Platform at the European Society of Medical Oncology Immuno-Oncology (ESMO-IO) 2025 Annual Congress
- Purple Biotech Reports Third Quarter 2025 Financial Results and Provides Business Update
- Purple Biotech Achieves Manufacturing Milestone for IM1240, a Tri-Specific Antibody from the CAPTN-3 Platform
- Purple Biotech Announces Receipt of Nasdaq Minimum Bid Price Notification
- Purple Biotech Receives Intention to Grant a European Patent Covering NT219 Combinations with Immunotherapies or MEK Inhibitors to Overcome Tumor Resistance
- Purple Biotech Announces Closing of Up To $18 Million Public Offering $6 million upfront with up to an additional $12 million of potential aggregate gross proceeds upon the exercise in full of short-term warrants
- Purple Biotech Announces Pricing of Up To $18 Million Public Offering
- Purple Biotech Announces New Data Supporting the Unique Design of CAPTN-3 Tri-Specific Antibody IM1240 in Collaboration with the Icahn School of Medicine at Mount Sinai
More ▼
